Inspire Medical Systems (INSP)
(Delayed Data from NYSE)
$143.74 USD
+5.92 (4.30%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $143.77 +0.03 (0.02%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth C Momentum D VGM
Price, Consensus and EPS Surprise
INSP 143.74 +5.92(4.30%)
Will INSP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INSP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INSP
Inspire Medical (INSP) Dips on FDA Recall of IPG Model 3028
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
INSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Why Is Inspire (INSP) Down 7.3% Since Last Earnings Report?
Three Reasons to Retain Inspire Medical (INSP) Stock for Now
Other News for INSP
Inspire Medical Systems, Inc. Announces CE Mark Certification under the European Union’s Medical Device Regulation for Inspire Therapy
Inspire announces CE mark certification under EU MDR for Inspire Therapy
Inspire announces EU MDR approved additional MRI conditions for Inspire Therapy
Med-tech and healthcare stocks with upside during 2Q earnings - Baird
Inspire Medical price target lowered by $63 at Truist, here's why